151 related articles for article (PubMed ID: 8893888)
21. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
22. [A phase II multicenter study of gemcitabine in non small cell lung cancers].
Le Chevalier T; Gottfried M; Gatzemeier U; Shepherd F; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Voi M; Ponzio A
Bull Cancer; 1997 Mar; 84(3):282-8. PubMed ID: 9207875
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for advanced non-small cell lung cancer (NSCLC).
Manegold C
Lung Cancer; 2002 Dec; 38 Suppl 3():S47-50. PubMed ID: 12468145
[No Abstract] [Full Text] [Related]
24. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
25. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
[TBL] [Abstract][Full Text] [Related]
27. Economic value of gemcitabine in non-small cell lung cancer.
Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
29. Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Metro G; Cappuzzo F; Finocchiaro G; Toschi L; Crinò L
Ann Oncol; 2006 May; 17 Suppl 5():v37-46. PubMed ID: 16807461
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of gemcitabine with concurrent radiotherapy on stage III,inoperable non-small cell lung cancer].
Li GZ; Zhang SH; Zhang Z; Wang RL
Ai Zheng; 2007 Dec; 26(12):1377-80. PubMed ID: 18076806
[TBL] [Abstract][Full Text] [Related]
31. A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine.
Natale R
Lung Cancer; 2005 Oct; 50 Suppl 1():S2-4. PubMed ID: 16291427
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
33. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Anderson H; Hopwood P; Stephens RJ; Thatcher N; Cottier B; Nicholson M; Milroy R; Maughan TS; Falk SJ; Bond MG; Burt PA; Connolly CK; McIllmurray MB; Carmichael J
Br J Cancer; 2000 Aug; 83(4):447-53. PubMed ID: 10945489
[TBL] [Abstract][Full Text] [Related]
34. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status Baka S; Ashcroft L; Anderson H; Lind M; Burt P; Stout R; Dowd I; Smith D; Lorigan P; Thatcher N
J Clin Oncol; 2005 Apr; 23(10):2136-44. PubMed ID: 15713598
[TBL] [Abstract][Full Text] [Related]
36. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
Martoni A; Di Fabio F; Guaraldi M; Piana E; Ramini R; Lelli G; Palomba G; Artioli F; Bandieri E; Robustelli Della Cuna G; Preti P
Am J Clin Oncol; 2001 Dec; 24(6):614-7. PubMed ID: 11801766
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer.
Zwitter M; Cufer T; Wein W
Neoplasma; 2001; 48(3):200-2. PubMed ID: 11583289
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
39. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
40. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
